Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Background: The Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI, Zoref-Lorenz et al, Blood, 2022) index, defined by the combined elevation in serum soluble CD25 (sCD25) and ferritin, has emerged as a promising prognostic tool for patients with newly diagnosed hematologic malignancies, demonstrating superior performance in predicting 500-day mortality compared to HLH-2004 criteria. However, previous studies were retrospective, with a substantial proportion (65%) of patients suspected clinically to have HLH. We evaluated the performance of the OHI index in an unselected, prospective cohort of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients.

Methods: We analyzed the predictive utility of the OHI index in 331 newly diagnosed DLBCL patients enrolled from 2002-2015 in the prospective Iowa/Mayo Molecular Epidemiology Resource cohort. Ferritin and sCD25 levels were quantified in pre-treatment serum samples using R&D ELISA kits. OHI values were also optimized based on 500-day mortality in the cohort using receiver operating curve analysis with internal validation. Patients were classified as OHI+ using the original and newly optimized thresholds for sCD25 and ferritin. The primary endpoint was 500-day survival, and the secondary endpoints were event-free survival (EFS) at 24 months (EFS24), EFS, and overall survival (OS). The predictive capability of the OHI index was evaluated using logistic regression to determine odds ratios (OR) and 95% confidence intervals (CI) for 500-day mortality and EFS24, as well as Cox regression to calculate hazard ratios (HR) and 95% CIs for EFS and OS.

Results: The median age at diagnosis of the 331 patients was 63.5 years (interquartile range, 54.5-74), and 168 (51%) were male. Using the original thresholds (sCD25 3,900 U/mL and ferritin 1,000 ng/mL), 4.2% of patients were OHI+, with a more than 5-fold higher 500-day mortality risk compared to OHI- patients (OR=5.6; CI 1.6-17, p<0.001).

After optimizing thresholds for sCD25 (2,400 U/mL) and ferritin (250 ng/mL) to predict 500-day mortality, 23.6% were OHI+ and the OHI+ group had a 9-fold higher 500-day mortality risk (OR=9.2; CI 4.0-24, p<0.001), with 31% mortality in the OHI+ vs 5% in the OHI- group. OHI+ patients exhibited more B-symptoms (35% vs 20%, p=0.027), elevated LDH levels (76% vs 34%, p<0.001), poorer performance status (Eastern Cooperative Oncology Group 2+: 38% vs 12%, p<0.001), and more advanced stage disease (Stage IV: 57% vs 38%, p<0.001), although the frequency of a high International Prognostic Index (IPI) was not statistically different between the groups (IPI 3-5: 44% vs 36%, p=0.28). After adjusting for age and IPI, OHI+ remained a strong predictor of 500-day mortality (OR=5.0; CI 1.9-13, p=0.001). Further adjustment for the cell of origin did not impact the results. The association of OHI+ status with 500-day mortality was similar in IPI 0-2 (OR=5.8; CI 1.2-29, p=0.033) and 3-5 (OR=6.8; CI 0.6-73, p=0.11).

OHI+ patients were also more likely to not achieve EFS24 (45% vs 13%), with a 3-fold greater risk after adjusting for age and IPI (OR=3.2; CI 1.5-6.5, p=0.0018). The OHI index also retained its predictive ability over longer-term follow-up (median 9.8 years for living patients) for both OS (HR=2.0; CI 1.0-4.0, p=0.040) and EFS (HR=2.2; CI 1.1-4.3, p=0.030) after adjusting for age and IPI.

Cytokine profiling using multiplex ELISA identified elevated inflammatory markers in OHI+ patients, underscoring the role of systemic inflammation in prognosis. The distribution of cytokines was significantly different between the groups, with consistently higher means in the OHI+ vs OHI- group, including IL1a (1,628 vs 759 pg/ml, p=0.008), CCL2 (1,020 vs 724 pg/ml, p=0.028), CXCL10 (165 vs 53 pg/ml, p<0.0001), and CXCL9 (380 vs 150 pg/ml, p<0.0001).

Conclusions: While the original OHI index for prediction of 500-day mortality was validated in this unselected cohort of newly diagnosed DLBCL patients, optimization of the OHI thresholds identified a larger OHI+ group (24%), enhanced the identification of hyperinflammation, improved predictive ability for early (500-day) mortality, and predicted EFS24 status and long-term OS. This underscores the clinical relevance of the OHI index, supports the need to evaluate disease-specific thresholds, and suggests its potential for use in routine management and as enrollment criteria in clinical trials for novel therapies.

Zoref-Lorenz:Sobi: Consultancy. Wang:Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck: Research Funding; Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie: Other: Advisory Board; InnoCare, AbbVie: Consultancy; Kite: Honoraria. Maurer:GenMab: Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Research Funding; Roche/Genentech: Research Funding. Feldman:Zeno Pharmaceuticals: Patents & Royalties; Seattle Genetics: Research Funding. Itchaki:Abbvie: Consultancy, Honoraria, Research Funding; Astra Zeneca: Consultancy, Honoraria, Research Funding; J&J: Consultancy, Honoraria, Research Funding; Medison: Consultancy; Eli Lilly: Consultancy. Nowakowski:F. Hoffmann-La Roche Limited: Consultancy; Zai Laboratory: Consultancy; Karyopharm Therapeutics: Consultancy; Daiichi Sankyo: Consultancy; ADC Therapeutics: Consultancy; Debiopharm: Consultancy; Curis: Consultancy, Research Funding; Genentech: Consultancy; Blueprint Medicines Corporation: Consultancy; Bantam Pharmaceutical, LLC: Consultancy; AbbVie Inc.: Consultancy; Selvita Inc: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; MorphoSys AG: Consultancy, Research Funding; Constellation Pharmaceuticals: Consultancy; Kymera Therapeutics: Consultancy; Segen: Consultancy; TG Therapeutics Inc: Consultancy; Incyte Corporation: Consultancy; Celgene Corporation: Consultancy, Research Funding; Fate Therapeutics: Consultancy; Ryvu Therapeutics: Consultancy; MEI Pharma: Consultancy. Habermann:Lilly: Other: Data Monitoring Committee. Link:Genentech: Research Funding. Ansell:ADC Therapeutics: Research Funding; SeaGen: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; Pfizer: Research Funding; Affimed: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Research Funding; AstraZeneca: Research Funding; Takeda: Research Funding. Novak:Bristol Myers Squibb: Research Funding. Goyal:Opna Bio, Seagen: Membership on an entity's Board of Directors or advisory committees; Recordati: Consultancy. Cerhan:BMS: Research Funding; Protagonist Therapeutics: Other: SMC; Genentech: Research Funding; GenMab: Research Funding. Jordan:Sobi Inc: Consultancy.